Variable | Hepatitis C virus + (N = 63) | Hepatitis C virus - (N = 138) | P |
---|---|---|---|
Age, years (median [IQR]) | 43.7 (39.4-47.0) | 43.5 (35.6-49.5) | 0.55 |
Men, no. (%) | 53 (84.1) | 100 (72.5) | 0.08 |
Category C of the CDC, no. (%) | 13 (20.6) | 49 (35.5) | 0.04 |
IDU, no. (%) | 58 (92.1) | 11 (8.0) | <0.001 |
MSM, no. (%) | 0 | 56 (40.6) | <0.001 |
Viral load < 50 copies/mL, no. (%) | 44 (69.8) | 90 (65.2) | 0.63 |
CD4 cell count, cells/μL (median [IQR]) | 530 (280-750) | 495 (317.5-652.5) | 0.86 |
On antiretroviral therapy, no. (%) | 56 (88.9) | 115 (83.3) | 0.39 |
Duration of antiretroviral therapy exposure, years (median [IQR]) | 9.0 (3.75-10.0) | 6.0 (1.88-10.0) | 0.25 |
Non nucleoside analog-based regimen, no. (%) | 17 (27.0) | 53 (38.7) | 0.11 |
Protease inhibitor-based regimen, no. (%) | 36 (57.1) | 58 (42.3) | 0.07 |
Lipodystrophy1, no. (%) | 19 (30.2) | 47 (34.1) | 0.63 |
Current smoker, no. (%) | 53 (84.1) | 71 (51.4) | <0.001 |
Dyslipidemia, no. (%) | 12 (19) | 56 (40.6) | 0.002 |
Lipid-lowering therapy | 5 (7.9) | 42 (30.4) | <0.001 |
Hypertension, no. (%) | 8 (12.7) | 29 (21.0) | 0.17 |
Diabetes, no. (%) | 3 (4.8) | 14 (10.1) | 0.28 |
Pre-existing cardiovascular disease, no. (%) | 2 (3.2) | 3 (2.2) | 0.65 |
Body mass index, Kg/m2 (median [IQR]) | 24.05 (21.56-27.86) | 25.0 (21.99-28.32) | 0.48 |
Hepatitis B virus, no. (%) | 0 | 4 (3.0) | 0.30 |
Hepatitis C viral load, copies/mL (median [IQR]) | 748,056 (145,564-3,204,245) | - | - |
APRI index (median [IQR]) | 0.67 (0.39-1.29) | 0.22 (0.18-0.31) | <0.001 |
Genotypes 1 and 4 (n = 37) | 0.67 (0.40-1.11) | ||
Genotypes 2 and 3 (n = 24) | 0.73 (0.38-1.62) | 0.933 | |
FIB-4 index (median [IQR]) | 1.40 (0.98-3.27) | 0.91 (0.66-1.17) | <0.001 |
Genotypes 1 and 4 (n = 37) | 1.52 (1.09-2.74) | ||
Genotypes 2 and 3 (n = 24) | 1.42 (0.91-4.14) | 0.863 | |
Waist-to-hip ratio (median [IQR]) | 0.94 (0.89-0.98) | 0.93 (0.88-0.98) | 0.72 |
Metabolic syndrome2, no. (%) | 14 (22.2) | 42 (30.4) | 0.31 |
Framingham risk at 10 years4, % (median [IQR]) | 5 (2-8) | 4 (1-10) | 0.69 |
Systolic blood pressure, mm Hg (median [IQR]) | 122 (114-133) | 130 (118.5-142) | 0.006 |
Diastolic blood pressure, mm Hg (median [IQR]) | 76 (69-83) | 79 (71-85) | 0.21 |
Fasting total cholesterol, mg/dL (median [IQR]) | 163 (146-186) | 185 (158.8-213.3) | 0.001 |
Fasting LDL-cholesterol, mg/dL (median [IQR]) | 104 (86-123) | 119.5 (100-140) | 0.001 |
Fasting HDL-cholesterol, mg/dL (median [IQR]) | 41.2 (34.5-50.2) | 43.5 (36.9-51.2) | 0.56 |
Fasting triglycerides, mg/dL (median [IQR]) | 131 (86-171) | 137.5 (94.8-197.5) | 0.30 |
Fasting glucose, mg/dL (median [IQR]) | 87.0 (81-99) | 87.0 (80.8-97) | 0.93 |
VCAM-1, ηg/mL (median [IQR]) | 931.4 (707.8-1606.5) | 766.6 (630.3-974.5) | <0.001 |
ICAM-1, ηg/mL (median [IQR]) | 492.6 (354.4-713.1) | 314.3 (251.9-408.3) | <0.001 |
Baseline brachial artery diameter, cm (median [IQR]) | 4.30 (3.87-4.53) | 4.14 (3.60-4.60) | 0.20 |
Brachial artery FMD, % (median [IQR]) | 6.21 (2.86-9.62) | 5.54 (2.13-9.13) | 0.37 |
Genotypes 1 and 4 (n = 37) | 6.78 (2.01-11.80) | ||
Genotypes 2 and 3 (n = 24) | 5.09 (3.02-8.29) | 0.323 | |
Brachial artery nitroglycerine MD, % (median [IQR]) | 18.35 (15.27-25.65) | 19.68 (12.31-24.57) | 0.86 |
Genotypes 1 and 4 (n = 37) | 19.44 (15.50-28.16) | ||
Genotypes 2 and 3 (n = 24) | 18.22 (11.62-22.08) | 0.163 | |
Carotid IMT, mm (median [IQR]) | 0.61 (0.55-0.65) | 0.60 (0.53-0.72) | 0.39 |
Genotypes 1 and 4 (n = 37) | 0.59 (0.52-0.65) | ||
Genotypes 2 and 3 (n = 24) | 0.63 (0.55-0.68) | 0.153 | |
Carotid plaques, no. (%) | 25 (39.7) | 48 (38.4) | 0.53 |